Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EPS (Basic) (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed EPS (Basic) for 13 consecutive years, with -$1.37 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Basic) fell 234.15% year-over-year to -$1.37; the TTM value through Mar 2026 reached -$4.15, down 260.87%, while the annual FY2025 figure was -$3.19, 215.84% down from the prior year.
  • EPS (Basic) hit -$1.37 in Q1 2026 for Viking Therapeutics, up from -$1.39 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.19 in Q2 2023 and bottomed at -$1.39 in Q4 2025.
  • Average EPS (Basic) over 5 years is -$0.43, with a median of -$0.25 recorded in 2023.
  • Year-over-year, EPS (Basic) increased 17.39% in 2023 and then plummeted 334.37% in 2025.
  • Viking Therapeutics' EPS (Basic) stood at -$0.26 in 2022, then rose by 3.85% to -$0.25 in 2023, then decreased by 28.0% to -$0.32 in 2024, then tumbled by 334.37% to -$1.39 in 2025, then rose by 1.44% to -$1.37 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$1.37, -$1.39, and -$0.81 for Q1 2026, Q4 2025, and Q3 2025 respectively.